GeneDx Holdings (WGS) Cost of Revenue (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Cost of Revenue data on file, last reported at $34.0 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $34.0 million, up 18.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $134.8 million (up 9.03% YoY), and the FY2025 annual result was $129.4 million, up 16.49% from the prior year.
• Cost of Revenue fell to $34.0 million in Q1 2026 per WGS's latest filing, from $36.7 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $77.7 million in Q4 2022 and troughed at $15.2 million in Q2 2023.
• A 5-year average of $31.8 million and a median of $28.6 million in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue sank 79.97% in 2023, then soared 294.36% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $77.7 million in 2022, then slumped by 79.97% to $15.6 million in 2023, then soared by 294.36% to $61.4 million in 2024, then plunged by 40.15% to $36.7 million in 2025, then slipped by 7.29% to $34.0 million in 2026.
• Business Quant data shows WGS's Cost of Revenue at $34.0 million in Q1 2026, $36.7 million in Q4 2025, and $32.2 million in Q3 2025.